Literature DB >> 11865417

Emergence of autologous neutralization-resistant variants from preexisting human immunodeficiency virus (HIV) quasi species during virus rebound in HIV type 1-infected patients undergoing highly active antiretroviral therapy.

Feng-Xiang Wang1, Tetsuya Kimura, Kumiko Nishihara, Kazuhisa Yoshimura, Atsushi Koito, Shuzo Matsushita.   

Abstract

The role of neutralizing antibodies (NAbs) during virus rebound in human immunodeficiency virus type 1 (HIV-1)-infected patients undergoing highly active antiretroviral therapy is poorly understood. Three patients in this study had NAbs to preexisting autologous HIV-1 and an episode of virus rebound after a prolonged period of virus suppression. To investigate the influence of NAbs on virus evolution, envelope genotypes of preexisting and rebound viruses were examined. Phylogenetic analysis of env (V1-V5) sequences indicated that rebound viruses had evolved from or preexisted in baseline populations. By use of envelope pseudotype viruses, rebound viruses were found to be significantly resistant to neutralization by autologous antibody in all 3 patients, indicating that rebound viruses were selected by NAbs. The site responsible for conferring neutralization resistance against autologous antibody was identified in the upstream C3 region in 2 of 3 patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11865417     DOI: 10.1086/339015

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  7 in total

1.  Enhanced exposure of human immunodeficiency virus type 1 primary isolate neutralization epitopes through binding of CD4 mimetic compounds.

Authors:  Kazuhisa Yoshimura; Shigeyoshi Harada; Junji Shibata; Makiko Hatada; Yuko Yamada; Chihiro Ochiai; Hirokazu Tamamura; Shuzo Matsushita
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

2.  IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART.

Authors:  Feng-Xiang Wang; Yan Xu; Julie Sullivan; Emily Souder; Elias G Argyris; Edward A Acheampong; Jaime Fisher; Maria Sierra; Michael M Thomson; Rafael Najera; Ian Frank; Joseph Kulkosky; Roger J Pomerantz; Giuseppe Nunnari
Journal:  J Clin Invest       Date:  2005-01       Impact factor: 14.808

3.  Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.

Authors:  Junji Shibata; Kazuhisa Yoshimura; Akiko Honda; Atsushi Koito; Toshio Murakami; Shuzo Matsushita
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

4.  Highly efficient neutralization by plasma antibodies from human immunodeficiency virus type-1 infected individuals on antiretroviral drug therapy.

Authors:  Raiees Andrabi; M A Makhdoomi; Rajesh Kumar; Manju Bala; Hilal Parray; Arjun Gupta; Ankita Kotnala; Velpandian Thirumurthy; Kalpana Luthra
Journal:  J Clin Immunol       Date:  2014-03-29       Impact factor: 8.317

5.  Effect of a protease inhibitor-induced genetic bottleneck on human immunodeficiency virus type 1 env gene populations.

Authors:  Kathryn M Kitrinos; Julie A E Nelson; Wolfgang Resch; Ronald Swanstrom
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

6.  CD4+ T cell targeting of human immunodeficiency virus type 1 (HIV-1) peptide sequences present in vivo during chronic, progressive HIV-1 disease.

Authors:  Eli Boritz; Eric L Rapaport; Thomas B Campbell; John R Koeppe; Cara C Wilson
Journal:  Virology       Date:  2006-12-13       Impact factor: 3.616

7.  Immunogenicity of a polyvalent HIV-1 candidate vaccine based on fourteen wild type gp120 proteins in golden hamsters.

Authors:  Ali Azizi; David E Anderson; Masoud Ghorbani; Katrina Gee; Francisco Diaz-Mitoma
Journal:  BMC Immunol       Date:  2006-10-31       Impact factor: 3.615

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.